In real-world ophthalmic practice, the management of AMD relies on precise longitudinal evaluation to determine the timing of anti-vascular endothelial growth factor (anti-VEGF) injections, assess treatment response, and predict recurrence risk. The gene discussed is VEGFA; the disease is age-related macular degeneration.